Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES. Academic Article uri icon

Overview

publication date

  • August 9, 2024

Research

keywords

  • Antibodies, Monoclonal, Humanized
  • Cardiovascular Diseases
  • Lipoprotein(a)

Identity

Scopus Document Identifier

  • 85201029227

Digital Object Identifier (DOI)

  • 10.1093/eurjpc/zwae110

PubMed ID

  • 38501249

Additional Document Info

volume

  • 31

issue

  • 10